Conference Reports for NATAP

Back

AIDS 2002 Barcelona   Barcelona, Spain July 7-12 2002     Barcelona Italian Heart Disease Study Withdrawn - (8/25/02)   New PI Boosted Regimen: Saquinavir/ritonavir - (8/25/02)   Another Lackluster Study on Predicting Response to HAART by CD4 - (8/12/02)   Nuke Sparing Regimen: Kaletra + 1000 mg Saquinavir - (8/12/02)   FRAM Study and Lipodystrophy: lipodystrophy study presented at Barcelona and an interview with the study author Carl Grunfeld - (8/9/02)   Kaletra Studies at Barcelona - (8/8/02)   XIVth International AIDS Conference, Barcelona, Spain - written by David Margolis, MD, University of Texas - (8/8/02)   Study Finds Increase in AST After starting ART Increases Risk For death More Than Having HCV - (8/5/02)   Hepatitis Highlights from Intl AIDS Conference Barcelona - (8/1/02)   Retrospective analysis of the use of Tenofovir DF in a private practice - (8/1/02)   Metabolic Complications of HIV and its Therapies: What Did We Learn in Barcelona? - (7/25/02)   New Information on Liver & Kidney Transplants in HIV+ Patients - (7/24/02)   Studies Find Low-Level HIV Drug Resistance During Therapy and Interruptions; Does 3 month Interruption Help or Harm? - (7/24/02)   New Drugs: TMC114 (PI) and TMC125 (NNRTI) - (7/24/02)   Liver Transplants Successful in HIV+ - (7/18/02)   Tenofovir and DDI EC Interactions: TDF raises ddI levels 50-70% - (7/18/02)   HAART Did Not Prevent or Reduce Rates of Anal Intraepithelial Neoplasia; Screening Recommended For All - (7/17/02)   Anal Sex Increases Risk For Heterosexual HIV Transmission - (7/17/02)   A Lipodystrophy Reformation? - (7/16/02)   Nevirapine Hepatotoxicity - (7/16/02)   FDA GRANTS PRIORITY REVIEW TO PEGASYS (peginterferon alfa-2a) AND RIBAVIRIN COMBINATION FOR TREATMENT OF HEPATITIS C - (7/16/02)   Short & Long Term Adherence/Education Programs - (7/16/02)   Once Daily - d4T, AZT - (7/15/02)   HGH for AIDS Related Wasting - (7/15/02)   Does Liver Disease Improve for HCV Therapy Nonresponders? - (7/15/02)   Human Growth Hormone for Lipodystrophy: daily vs alternate day dosing - (7/15/02)   GUESS Study: inconsistencies by experts in interpreting resistance test results - (7/15/02)   Kaletra in Women - (7/15/02)   New Integrase Inhibitor, S-1360 - (7/12/02)   GIGHAART: 8-week Treatment Interruption Improves Viral Response in Deep Salvage - (7/12/02)   Tenofovir vs d4T: 48 Week Study Results in Treatment Naïve - (7/12/02)   PegIntron + Ribavirin in HIV/HCV Coinfected Patients - (7/11/02)   Body Changes: indinavir vs nevirapine vs 3TC, plus d4T/ddI. Protease Inhibitors Appear to Increase Risk For Premature Heart Disease - (7/11/02)   Lipoatrophy Didn't Improve: switch to PI-Sparing - (7/10/02)   Kaletra Did Not Result in Methadone Withdrawal - (7/10/02)   Kaletra Once Daily; Efavirenz in Patients with Highly Advanced HIV - (7/9/02)   Tenofovir vs D4T 48 Week Study Results: cholesterol, triglycerides - (7/9/02)   New HIV Drugs / Hep C: quicker HCV progression nin coinfection; sumptomatic hyperlactatemia in coinfected patients taking RBV; PegIntron/RBV in coinfected - (7/8/02)   T-20: new class of drug about to enter market; fusion inhibitor - (7/8/02)   Opening Ceremony at Barcelona - (7/8/02)